A nurse is providing instruction to a new nurse about caring for clients who are receiving diuretic therapy to treat heart failure.
The nurse should explain that which of the following medications puts clients at risk for both hyperkalemia and hyponatremia?

This question tests the application of the nursing process phases. It requires identifying the specific stage where the nurse compares the patient's current status and clinical outcomes against the established goals to determine the success of the implemented interventions and the need for plan modifications.

Choice A rationale

The evaluation phase involves comparing the patient’s health status with the goals and outcomes defined in the care plan. Monitoring progress after a new medication regimen is a classic example of evaluating the effectiveness of a planned clinical intervention.

Choice B rationale

The planning phase involves setting measurable goals, outcomes, and nursing interventions based on the assessment data. While the nurse plans for the future, the action of monitoring ongoing progress is an evaluative step, not the creation of the initial care plan.

Choice C rationale

The assessment phase is the collection of patient data, including health history, physical examination, and diagnostic results. Monitoring progress happens after interventions have been initiated, whereas assessment occurs before and during the continuous data collection process to identify patient needs.

Choice D rationale

The implementation phase is the actual execution of nursing interventions and actions. While the nurse performs the monitoring, the cognitive process of determining how well the medication is working by comparing patient status to outcomes is defined as the evaluation phase.

This question evaluates the understanding of parenteral drug administration routes. It requires identifying the pharmacological advantages of avoiding the gastrointestinal tract, specifically how parenteral routes bypass initial hepatic metabolism, thereby ensuring greater drug bioavailability compared to drugs that undergo significant first-pass metabolism.

Choice A rationale

Parenteral drugs are administered via routes like IV or IM, avoiding the stomach entirely. Absorption kinetics are not related to gastric contents, as the medication is delivered directly into the systemic circulation or muscle tissue for uptake.

Choice B rationale

The first-pass effect refers to the metabolic breakdown of oral drugs by the liver before they reach systemic circulation. Parenteral routes, such as intravenous administration, bypass this process entirely, allowing the drug to reach target sites without initial hepatic degradation.

Choice C rationale

Stomach pH only affects the absorption of orally administered drugs that must survive the gastric environment and cross the mucosal lining. Parenteral medications are delivered outside of the digestive tract, so gastric pH has no impact on their bioavailability.

Choice D rationale

Parenteral drugs exert systemic effects by circulating through the bloodstream to reach various target tissues and organs throughout the body. They do not depend on the intestines for their action, as they are not administered via the enteral route.